Aarti Drugs Q2 FY27: revenue up 26.6% to ₹826 Cr, net profit up 83.2% to ₹83 Cr
Results · Finvezto · 3 Nov 2026 · Aarti Drugs (AARTIDRUGS)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 826 | +17.6% | +26.6% |
| Operating profit | 135 | +37.9% | +60.6% |
| Net profit | 83 | +65.3% | +83.2% |
| Operating margin | 16.4% | +2.4 pp | +3.5 pp |
| Net margin | 10.0% | +2.9 pp | +3.1 pp |
Key points
- Aarti Drugs reported consolidated total revenue of Rs 828.8 crore for Q2 FY27, up 27% from Rs 652.9 crore in Q2 FY26, with EBITDA rising 63% to Rs 137.9 crore and Profit After Tax surging 83% to Rs 82.8 crore. NSE filing
- Growth was broad-based across segments, with formulation revenue rising 58% to Rs 130.0 crore and specialty chemicals expanding 92% to Rs 71.8 crore driven by the scale-up at Sayakha. NSE filing
- Revenue was ₹826 Cr, up 26.6% on a year earlier and up 17.6% on the quarter before. Finvezto data
Other figures
- Consolidated Gross Profit (includes other income): ₹330 Cr (+35.0% YoY)
What to watch
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 9.1%, 13.3%, 14.0%, 16.4%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 41, 55, 50, 83.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.